SV2A and epilepsy: However, brivaracetam does not seem to be as effective in the treatment of epilepsy as it was previously thought, taking into consideration its superiority over levetiracetam in experimental studies [102, 103], where it was 15–30 times more potently bound to the SV2A molecule than levetiracetam and it entered the brain much faster due to its lipophilic properties [104].